Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan
· Delayed Price · Currency is TWD 39.65
-0.15 (-0.38%)
May 2, 2025, 2:00 PM CST
TPEX:7427 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 155.06 | 179.55 | 111.08 | 62.79 | 67.02 | Upgrade
|
| Short-Term Investments | 427.7 | 297 | 136.5 | 62.32 | - | Upgrade
|
| Cash & Short-Term Investments | 582.76 | 476.55 | 247.58 | 125.1 | 67.02 | Upgrade
|
| Cash Growth | 22.29% | 92.48% | 97.90% | 86.65% | 74.65% | Upgrade
|
| Accounts Receivable | 0.72 | 0.09 | - | - | - | Upgrade
|
| Other Receivables | 0.67 | 0.47 | 0.1 | 0.07 | - | Upgrade
|
| Receivables | 1.39 | 0.56 | 0.1 | 0.07 | - | Upgrade
|
| Inventory | 3.01 | 6.16 | - | - | - | Upgrade
|
| Prepaid Expenses | 1.99 | 0.38 | 0.76 | 0.01 | - | Upgrade
|
| Other Current Assets | 9.55 | 1.8 | 3.01 | 0.22 | 0.14 | Upgrade
|
| Total Current Assets | 598.7 | 485.45 | 251.45 | 125.41 | 67.16 | Upgrade
|
| Property, Plant & Equipment | 13.63 | 16.01 | 0.12 | 0.12 | 0.81 | Upgrade
|
| Other Intangible Assets | 27.53 | 29.16 | 15.27 | 88.6 | 48.24 | Upgrade
|
| Long-Term Deferred Charges | 1.21 | 6.96 | 5.94 | 3.5 | - | Upgrade
|
| Other Long-Term Assets | 21.52 | 23.67 | 15.92 | 12.34 | 9.65 | Upgrade
|
| Total Assets | 662.6 | 561.25 | 288.71 | 229.96 | 125.85 | Upgrade
|
| Accounts Payable | 0.11 | 0.62 | 0.83 | 0.86 | 0.08 | Upgrade
|
| Accrued Expenses | 17.6 | 10.05 | 10.63 | 20.42 | 4.92 | Upgrade
|
| Current Portion of Leases | 2.9 | 2.87 | - | - | - | Upgrade
|
| Other Current Liabilities | 1.22 | 2.39 | 0.59 | 0.33 | 0.31 | Upgrade
|
| Total Current Liabilities | 21.82 | 15.93 | 12.05 | 21.61 | 5.3 | Upgrade
|
| Long-Term Leases | 7.45 | 10.88 | - | - | - | Upgrade
|
| Total Liabilities | 29.28 | 26.81 | 12.05 | 21.61 | 5.3 | Upgrade
|
| Common Stock | 436.44 | 383.58 | 292.87 | 225.75 | 185.75 | Upgrade
|
| Additional Paid-In Capital | 742.07 | 591.12 | 363.05 | 221.94 | 138.28 | Upgrade
|
| Retained Earnings | -545.18 | -440.26 | -379.26 | -239.34 | -203.48 | Upgrade
|
| Shareholders' Equity | 633.32 | 534.44 | 276.66 | 208.36 | 120.55 | Upgrade
|
| Total Liabilities & Equity | 662.6 | 561.25 | 288.71 | 229.96 | 125.85 | Upgrade
|
| Total Debt | 10.36 | 13.75 | - | - | - | Upgrade
|
| Net Cash (Debt) | 572.4 | 462.8 | 247.58 | 125.1 | 67.02 | Upgrade
|
| Net Cash Growth | 23.68% | 86.93% | 97.90% | 86.65% | 74.65% | Upgrade
|
| Net Cash Per Share | 13.89 | 12.76 | 10.25 | 5.93 | 4.23 | Upgrade
|
| Filing Date Shares Outstanding | 43.64 | 38.36 | 29.29 | 22.57 | 18.58 | Upgrade
|
| Total Common Shares Outstanding | 43.64 | 38.36 | 29.29 | 22.57 | 18.58 | Upgrade
|
| Working Capital | 576.87 | 469.52 | 239.41 | 103.8 | 61.86 | Upgrade
|
| Book Value Per Share | 14.51 | 13.93 | 9.45 | 9.23 | 6.49 | Upgrade
|
| Tangible Book Value | 605.79 | 505.28 | 261.39 | 119.75 | 72.31 | Upgrade
|
| Tangible Book Value Per Share | 13.88 | 13.17 | 8.93 | 5.30 | 3.89 | Upgrade
|
| Machinery | 7.63 | 5.69 | 3.2 | 3.21 | 3.18 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.